PG-208

PG-208 is an early-stage bispecific antibody therapeutic currently in the discovery phase for the treatment of cancer. Developed by Progen Pharmaceutical in partnership with Yuhan Corporation, the drug utilizes Progen's proprietary bispecific antibody platform. As a bispecific antibody, it is designed to simultaneously bind to two different antigens or epitopes, potentially enhancing tumor targeting or immune system recruitment. While the specific molecular targets have not been publicly disclosed, the modality suggests a mechanism involving dual-antigen targeting to improve therapeutic efficacy or overcome resistance mechanisms in oncology.